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ABSTRACT
Objective To review the association between current
enterovirus infection diagnosed with molecular testing
and development of autoimmunity or type 1 diabetes.
Design Systematic review and meta-analysis of
observational studies, analysed with random effects
models.
DatasourcesPubMed(untilMay2010)andEmbase(until
May 2010), no language restrictions, studies in humans
only;referencelistsofidentifiedarticles;andcontactwith
authors.
Study eligibility criteria Cohort or case-control studies
measuringenterovirusRNAorviralproteininblood,stool,
or tissue of patients with pre-diabetes and diabetes, with
adequate data to calculate an odds ratio and 95%
confidence intervals.
ResultsThe 24 papersand two abstracts(all case-control
studies) that met the eligibility criteria included 4448
participants.Studydesignvariedgreatly,withahighlevel
of statistical heterogeneity. The two separate outcomes
were diabetes related autoimmunity or type 1 diabetes.
Meta-analysis showed a significant association between
enterovirus infection and type 1 diabetes related
autoimmunity (odds ratio 3.7, 95% confidence interval
2.1 to 6.8; heterogeneity χ
2/df=1.3) and clinical type 1
diabetes (9.8, 5.5 to 17.4; χ
2/df=3.2).
Conclusions There is a clinically significant association
between enterovirus infection, detected with molecular
methods, and autoimmunity/type 1 diabetes. Larger
prospective studies would be needed to establish a clear
temporal relation between enterovirus infection and the
development of autoimmunity and type 1 diabetes.
INTRODUCTION
Type 1 diabetes is believed to result from a complex
interplay between genetic predisposition, the immune
system, and environmental factors.
1 In recent decades
there has been a rapid rise in the incidence of child-
hood type 1 diabetes worldwide, especially in those
under the age of 5.
2-6 In Europe, from 1989-2003 the
average annual increase was 3.9%, too fast to be
accounted for by genetics alone.
4 Evidence in support
of a putative role for viral infections in the develop-
ment of type 1 diabetes comes from epidemiological
studies that have shown a significant geographical var-
iation in incidence, a seasonal pattern to disease
presentation,
2378 and an increased incidence of dia-
betes after enterovirus epidemics.
9
Enteroviruses are perhaps the most well studied
environmental factor in relation to type 1 diabetes. A
possible link was first reported by Gamble et al in
1969,
10 with many subsequent studies, in humans and
animal models of diabetes, showing an association,
particularly with coxsackievirus B-4. Higher rates of
enterovirus infection, defined by detection of entero-
virusIgMorIgG,orboth,viralRNAwithreversetran-
scription polymerase chain reaction (RT PCR), and
viral capsid protein, have been found in patients with
diabetes at diagnosis compared with controls.
11-17
Prospective studies have also shown more enterovirus
infections in children who developed islet auto-
antibodies or subsequent diabetes, or both; as well as
a temporal relation between infection and
autoimmunity.
1318-20
The relation between enterovirus infection and dia-
betes is not consistent across all studies,
21-24 however,
and the subject remains controversial.
25 Furthermore,
in animal models viral infections might also protect
from diabetes.
25 A systematic review of coxsackie B
virus serological studies did not show an association
with type 1 diabetes,
26 but to date there has been no
systematic review of molecular studies. Based on the
hypothesis that enterovirus infection increases the
risk of pancreatic islet autoimmunity or type 1 dia-
betes, or both, we carried out a systematic review of
controlled studies that used molecular virological
methods to investigate the association between enter-
oviruses and type 1 diabetes.
METHODS
Two reviewers (WGY and MEC) independently con-
ductedasystematicsearchforcontrolledobservational
studies of enterovirus and type 1 diabetes mellitus.
Databases searched were PubMed (from 1965 to May
2010) and Embase (from 1974 to May 2010). Search
terms (exploded, all subheadings) used were: ‘diabetes
mellitus’, ‘enterovirus’, ‘coxsackievirus’, ‘ECHO-
virus’, ‘polymerase chain reaction’, ‘PCR’, ‘RNA’,
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was limited to studies in humans in any language and
was supplemented by hand searching reference lists in
theidentifiedpapersandbydirectcontactwithauthors.
Studies were eligible for inclusion if they were case-
control or cohort studies (including those published as
letters or abstracts); measured enterovirus RNA or
viralcapsidproteininblood,stool,ortissueofpatients
withpre-diabetesanddiabetes;andprovidedadequate
data to enable calculation of odds ratios and 95% con-
fidence intervals. No restrictions were placed on the
study population. We included only those studies that
used molecular methods for viral detection (such as
RT-PCR (reverse transcription-polymerase chain
reaction), in situ hybridisation, or immunostaining for
detection of viral capsid protein) to identify current or
recent infection and because molecular testing is now
standard for diagnosis of acute enterovirus infection.
The results of identified studies were classified into
two groups, pre-diabetes and diabetes, depending on
whether autoimmunity or type 1 diabetes was the out-
come. There were four main categories of cases: auto-
antibody positive, newly diagnosed type 1 diabetes,
established type 1 diabetes, and eventual type 1
diabetes. The latter three were combined into the dia-
betes group.
We calculated unadjusted odds ratios with 95% con-
fidenceintervalsandPvaluesforenterovirusidentifica-
tioninpatientswithpre-diabetesversusnodiabetesand
patients with diabetes versus no diabetes from the pub-
lished figures using the Mantel-Haenszel method. The
analysis was performed with both fixed and random
effects models. Because of the presence of significant
heterogeneity we have presented only the results from
randomeffectsmodels.Combinedoddsratioswerealso
calculated for different subgroups of studies according
to study design. Statistical heterogeneity was explored
with Cochrane’s Q test and the I
2 statistic, which pro-
vides the relative amount of variance of the summary
effect caused by heterogeneity between studies.
We assessed study quality using the Newcastle-
Ottawa quality assessment scale (NOS) for case-
control studies, as recommended by Cochrane
collaboration.
27 Three areas were evaluated—selec-
tion, comparability, and exposure—giving a possible
total score 9, with 5 or more classed as good methods.
Inthecomparabilitycategory,studieswereassessedas
to whether they controlled for age and sampling time
Table 1 |Summary of molecular studies investigating pre-diabetes and enteroviruses
Study Country
Cases/
controls Cases
Autoantibodies
detected Age in cases Controls
Method of
detection EV type sequenced
Al-Shaheeb,
2010
30
Australia 13/198 Autoantibody positive
children with first
degree relative with
T1DM
At least two of ICA,
GADA, IA2A, or IAA
Birth cohort from VIGR
study
Children from same
cohort negative for
autoantibody
EV RNA in serum
(RT-PCR)
—
Coutant, 2002
32 France 5/49 Autoantibody positive
siblings of probands
with diabetes
ICA, GADA Age 2.4-16.5 Healthy children
matched for age, sex,
place, and sampling
date
EV RNA in serum
(RT-PCR)
—
Graves, 2003
22 USA
13/13 Autoantibody positive
(eventual); sibling
offspring cohort At least one of IAA,
GADA, or ICA
From DAISY cohort
study, children at
moderate to highriskof
developing T1DM
Age matched children
from same cohort
negative for
autoantibody
EVRNAinserum,
saliva,andrectal
swab (RT-PCR)
—
13/26 Autoantibody positive
(eventual); newborn
screened cohort
Moya-Suri,
2005
33
Germany 50/50 Autoantibody positive At least one of IAA,
GADA, ICA, or IA2A
Median age 12,
IQR 10-14
Children from same
cohort negative for
autoantibody
EV RNA in serum
(RT-PCR)
CVB-4, CVB-2,
CVB-6
Salminen,
2003
20
Finland 41/196 Autoantibody positive
children(samplestaken
6 months before
seroconversion)
At least one of ICA,
GADA, IAA, or IA2A
Birth cohort from DIPP
study
Children from same
cohort negative for
autoantibody
EV RNA in serum
(RT-PCR)
—
Sadeharju,
2003
28
Finland 19/84 Autoantibody positive
(eventual), from Trial to
Reduce IDDM in
Genetically at Risk
(TRIGR) study
At least one of IAA,
GADA, or IA2A
Birth cohort from TRIGR
study
Children from same
study cohort negative
for autoantibody and
matched for sex, HLA,
and intervention group
EV RNA in serum
(RT-PCR)
—
Salminen,
2004
29
Finland 12/53 Autoantibody positive
(eventual)
At least one Birth cohort from DIPP
study
Children from same
study cohort negative
for autoantibody
(matched for age, sex,
and HLA DQ haplotype)
EV RNA in stool
samples
(RT-PCR) and/or
serum
PV-3, CVA-9, CVB-3,
CVB-4, CVB-5, EV-3,
EV-11, EV-18,
EV-24, EV-25
Sarmiento,
2007
16
Cuba 32/63 First degree relatives
with ICA positive T1DM
ICA Meanage13.5(SD9.5),
range 1-46
Healthy people verified
negative for ICA with no
family history of
diabetes
EV RNA in serum
(RT-PCR)
—
T1DM=type 1 diabetes mellitus; ICA=islet cell autoantibody; GADA=glutamic acid decarboxylase autoantibody; IA2A=islet cell antigen antibody; IAA=insulin autoantibody; EV RNA=enterovirus
RNA; RT PCA=reverse transcription-polymerase chain reaction; IQR=interquartile range.
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incidence of enterovirus infection.
RESULTS
Our search returned a total of 114 publications and
abstracts. After review of titles and abstracts, we
identifiedandincluded25relevantpapers—twoletters
and23articles.Wealsoincludeddatafromtwostudies
published as abstracts only. All were case-control stu-
dies (six were nested case-control studies that used
samples collected prospectively
202228-30). One was
excluded because it was a pilot study
13 analysing the
Table 2 |Summary of molecular studies investigating type 1 diabetes (T1DM) and enteroviruses
Study Country
Cases/
controls Cases and details of diabetes
Age of cases (years unless
specified) Controls Method of detection
EV type
sequenced
Andreolet-
ti, 1997
14 France 12/15
Newly diagnosed with metabolic
decompensation
Mean 28.2 (SD 10.4)
Healthy adults
EV RNA in peripheral blood
(RT PCR)
CVB-3, CVB-
4 Previously diagnosed with
metabolic decompensation
Mean 32.6 (SD 13.3)
Buesa-
Gomez,
1994
60
USA 2/5 Fatal acute onset 14 months and 3 years Children who died from
non-diabetic causes
Coxsackie RNA in autopsy
pancreatic samples (RT PCR)
—
Clements,
1995
41
UK 14/45 Newly diagnosed Mean 3.9, range 1.4-6.0 Normalsubjectsmatchedforage,
sex, sample date, and place
EV RNA in serum (RT PCR) CVB-3, CVB-
4
Coutant,
2002
32
France 16/49 Newlydiagnosed(within1month
of diagnosis)
Range <6 Healthychildrenmatchedforage,
sex, sample date, and place
EV RNA in serum (RT PCR) —
Craig,
2003
58
Australia 206/160 Newlydiagnosed(within2weeks
of diagnosis)
Median 8.2, range 0.7-15.7 Children without diabetes from
community
EV RNA in plasma or stool
samples (RT PCR)
EV-71
Dahlquist,
2004
36
Sweden 600/600 Eventual diabetes, on Swedish
childhood diabetes register
Neonate People without diabetes from
same biobank
EV RNA in newborn blood spots
(RT PCR)
—
Dotta,
2007
46
Italy 6/26 Recent onset Range 14-50 Normal multi-organ donors EV vp1 immunostaining in
autopsy pancreatic samples
(Dako anti-vp1)
CVB-4
Foulis,
1990
38
UK 147/43 88 recent onset (duration <1 year
), 59 established (duration
1-19 years)
Range 1-37 Normalautopsypancreasesfrom
11 neonates, 21 children, 11
adults
EV vp1 immunostaining in
autopsy pancreatic samples
—
Foy,
1995
35 UK
17/42 Newly diagnosed (on day of
diagnosis)
Median 11, range 2-35
Patients without diabetes,
matched for age and sex
EV RNA in peripheral blood
(RT PCR)
—
38/42 Duration 2 months-10 years Median 11, range 3-16
Kawashi-
ma 2004
61
Japan 61/58 Type 1 diabetes Range 9 months - 40 years Healthy people EV RNA in serum (RT PCR) CVB-2, CVB-
3, CVB-4,
CVB-5
Lönnrot,
2000
31 Finland
11/34 Eventual diabetes, from DiMe
Study
Mean 8.4, range 2.6-17 Children from same study cohort
who did not develop T1DM or
autoantibodies
EV RNA in serum (RT PCR) —
47/34 Newly diagnosed Mean 4.4
Maha,
2003
34 Egypt
40/30 Recent onset (<1 year) Mean 11.30 (SD 2.16)
Normal healthy children
EV RNA in serum (RT PCR via
tissue culture)
CVB-4, CVB-
6 30/30 Duration >1 year Mean 11.80 (SD 2.70)
Moya-Suri,
2005
33
Germany 47/50 Newlydiagnosed(median5days
from diagnosis)
Median 13, IQR 11-15 Children from same study
negative autoantibodies
EV RNA in serum (RT PCR) CVB-4, CVB-
2, CVB-6
Nairn,
1999
12
UK 110/182 Newly diagnosed (within 1 week
from diagnosis)
Mean 7.1, range 3 months
-16 years
Children without diabetes
(matched for age, location, time
of sampling)
EV RNA in serum (RT PCR) PV1-3, CVA-
21, CVA-24,
EV-70
Oikarinen,
2007
39
Finland 12/10 Established(duration0-51years,
median 13)
Median 30, range 18-53 Patients without diabetes from
same hospital department
vp1 immunostaining in small
bowel mucosa (Dako anti-vp1)
—
Richard-
son,
2009
17
UK 72/119 Recent onset (8.2 (SD 4.1)
months from diagnosis)
Mean 12.65 (SD 1.1),
range 1-42
Normalautopsypancreasesfrom
11 neonates, 39 children and 69
adults
EV vp1 immunostaining in
autopsy pancreatic samples
(Dako anti-vp1)
—
Sarmiento,
2007
16
Cuba 34/68 Newly diagnosed (0.78 (SD 2.4)
days from diagnosis)
Mean 7.3 (SD 4.5),
range 1-15
Healthy subjects, verified ICA
negative and no family history of
diabetes
EV RNA in serum (RT PCR) —
Schulte,
2010
43
Nether-
lands
10/20 Newlydiagnosed(within1month
of diagnosis)
Mean 9.7, range 5-14 Children of same age range in
hospital with non-endocrine
disorders
EV RNA in peripheral blood
mononuclear cells (RT PCR)
HEV-B
Toniolo,
2010
44
Italy 112/58 Newly diagnosed Mean 6.8, median 9.0,
range 2-16
Healthy children EV RNA in peripheral blood
(RT PCR)
HEV-A, HEV-
B, HEV-C,
HEV-D
Yin,
2002
40
Sweden 24/24 Newly diagnosed (within 1 week
from diagnosis)
Mean 8.4, range 1.6-15.7 Healthy children from nearby
counties
EV RNA in PBMCs (RT PCR) CVB-5, EV-5,
CVB-4
Ylipaasto,
2004
42
Finland/
Germany
65/40 Duration: few weeks to 19 years Range 18-52 Non-diabetic pancreases (age-
sex matched)
EV RNA in autopsy pancreatic
samples (RNA probes and in situ
hybridisation)
—
EV RNA=enterovirus RNA; RT PCA=reverse transcription-polymerase chain reaction.
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20 Of the 26
remaining studies,eight contained more than one case
group
14162231-35 and these were analysed separately,
giving a total of 34 studies. Of these, nine were studies
of pre-diabetes (198 cases and 733 controls) and 25
werestudiesofdiabetes(1733casesand1784controls).
Characteristics of included studies
Thirty studies used RT-PCR or in situ hybridisation to
detect enterovirus RNA, while four performed immu-
nostaining for the enterovirus capsid protein vp1 on
autopsy pancreas specimens (tables 1 and 2). Within
the pre-diabetes group, all except two of the studies
defined autoimmunity as positivity for at least one
autoantibody associated with type 1 diabetes (table 1).
Study populations varied in age distribution. While
most studies investigated children and adolescents
(aged16andbelow),someincludedadultsuptoage53.
Quality of evidence
The Newcastle-Ottawa scoresranged from 3 to 8, with
24 studies scoring 5 or more (table 3), indicating rea-
sonably good methodological quality overall, with no
studies reporting a non-response rate.
Pre-diabetes
Figure 1 presents the individual and summary odds
ratio of the nine pre-diabetes studies . Odds ratios
Table 3 |Quality of evidence in molecular studies investigating type 1 diabetes (T1DM) and enteroviruses
Study
NHMRC level
of evidence*
Newcastle-
Ottawa scale
score
Diagnostic criteria for
autoimmunity and/or
type 1 diabetes given?
Cases and controls matched? Detailsofviral
detection
given? Age Sex HLA Place Sample time
Andreoletti,
1997
14
III-3 4 No No No No No No Yes
(referenced)
Al-Shaheeb,
2010
30
II 7 Yes No No No Yes Yes Yes
Buesa-Gomez,
1994
60
III-3 4 No No No No No No Yes
Clements,
1995
41
III-3 6 No Yes Yes No Yes Yes No
Coutant, 2002
32 III-3 6 No Yes Yes No Yes Yes Yes
Craig, 2003
58 III-3 6 Yes (diabetes register) No No No No Yes Yes
Dahlquist,
2004
36
II 7 Yes (diabetes register) Yes No No No No Yes
(referenced)
Dotta, 2007
46 III-3 5 No No No No No NA Yes
Foulis, 1990
38 III-3 3 No No No No No NA Yes
Foy, 1995
35 III-3 6 Yes Yes Yes No No No Yes
Graves, 2003
22 II 7 Yes for autoimmunity,
no for diabetes
Yes No No No No No
Kawashima,
2004
61
III-3 5 No No No No No No Yes
Lönnrot, 2000
31 II 6 No Yes Yes Yes No Yes Yes
Maha, 2003
34 III-3 5 No No No No No No Yes
Moya-Suri,
2005
33
III-3 7 Yes for autoimmunity,
no for diabetes
Yes Yes No No No Yes
Nairn, 1999
12 III-3 7 No Yes No No Yes Yes Yes
(referenced)
Oikarinen,
2007
39
III-3 4 No No No No No NA Yes
Richardson,
2009
17
III-3 4 No No No No No NA Yes
Sadeharju,
2003
28
II 8 Yes Yes Yes Yes No Yes Yes
(referenced)
Salminen,
2003
20
II 6 Yes Yes Yes Yes No No Yes
(referenced)
Salminen,
2004
29
II 7 Yes Yes Yes Yes No Yes Yes
Sarmiento,
2007
16
III-3 6 No Yes Yes No Yes Yes Yes
Schulte, 2010
43 III-3 4 No No No No No No Yes
Toniolo, 2010
44 III-3 7 Yes No No No Yes No Yes
Yin, 2002
40 III-3 7 No Yes Yes No Yes No Yes
Ylipaasto,
2004
42
III-3 5 No Yes Yes No No No Yes
NA=not available.
*II=nested case-control study; III-3=case-control study.
59
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3.7 (95% confidence interval 2.1 to 6.8; P<0.001).
There was some evidence for heterogeneity across
the studies (χ
2/df=1.34), but this value did not reach
significance (P=0.22). When we analysed the results
from the six nested case-control studies separately,
the summary odds ratio was 3.0 (1.5 to 6.0; P=0.002)
(table 4).
Three of the nested case-control studies also sepa-
rately examined the six or 12 month period preceding
the first appearance of autoantibodies.
2022 The sum-
maryoddsratiowas3.6(1.3to9.8;P=0.01).Fivestudies
alsosequencedtheHLAhaplotypesoftheirparticipants
and two included those with low risk HLA genotypes.
For those with high HLA risk haplotypes (five studies,
112 cases, 551 controls), the combined odds ratio was
3.5 (1.7 to 7.1; P<0.001).
202228-30 Only two studies (21
cases, 158 controls) included participants with low risk
HLA genotypes, with conflicting results (0.4, (0.04 to
4.8)
22 and 9.3 (1.9 to 45)
30), but the combined odds
ratio was not significant (2.3, 0.1 to 56; P=0.62).
Type 1 diabetes
Figure2showstheindividualandsummaryoddsratios
of the 25 studies of patients with type 1 diabetes . All
studies except one
32 showed an odds ratio over 1 for
enterovirus positivity in patients with diabetes. Odds
ratios ranged from 0.24 to 129, with a summary odds
ratio of 10 (5.5 to 17; P<0.001). There was significant
heterogeneityacrossthestudies(χ
2/df=3.21;P<0.001).
We carried out a subgroup analysis with respect to
method of enterovirus detection (RNA or capsid pro-
tein) and case selection (newly diagnosed v established
veventualdiabetes;table 5,fig2).Thecombinedodds
ratios for newly diagnosed, established, and eventual
diabetes were 13 (6 to 25), 11 (4 to 29), and 1.25 (0.2 to
7), respectively. The combined odds ratio of studies
that used RNA detection was 8.8 (4.7 to 17; P<0.001),
while for studies that performed immunostaining for
enterovirus capsid protein, the odds ratio was 15 (7.5
to 31). There was no significant heterogeneity across
studies that measured enteroviral vp1 protein, prob-
ably because of the similarity in study design.
We used sensitivity analyses to test the robustness of
the results by country and study quality. For the 19 stu-
dies conducted in Europe,
12141731-3335-44 the combined
odds ratio was 8.6 (4.3 to 17; P<0.001), with significant
heterogeneity (χ
2/df=3.75, P<0.001). The odds ratio
wascomparativelyhigherforthenon-Europeanstudies
(13.5, 7.1 to 26), with low heterogeneity, though there
was considerable overlap of the confidence intervals
betweenthetwogroups.Whenweexcludedthestudies
with poor methodological quality (Newcastle-Ottawa
score <5), the combined odds ratio was similar (8.9,
4.6 to 17; P<0.001). Subgroup analysis by HLA geno-
typewasnotperformedbecausenoneofthestudiesper-
formed HLA genotyping on all cases and controls.
DISCUSSION
This systematic review of 33 prevalence studies, invol-
ving 1931 cases and 2517 controls, shows a clinically
significant association between enterovirus infection
and islet autoimmunity or type 1 diabetes. The associa-
tion between enterovirus infection, detected with mole-
cular methods, and diabetes was strong, with almost 10
times the odds of enterovirus infection in children at
diagnosis of type 1 diabetes compared with controls
(9.8, 5.5 to 17.4), while the odds of infection was also
higher in children with pre-diabetes than in controls
(3.7,2.1to6.8).Therewassomeevidenceforgeographi-
cal differences; in non-European studies the odds ratio
was 13.5 (7.1 to 25.8) compared with 8.6 (4.3 to 17.3) in
European studies, though there was considerably over-
lap in the confidence intervals. While the findings from
this meta-analysis of observational studies cannot prove
that enterovirus infection has a causal role in pathogen-
esis ofdiabetes, the results provide additional support to
thedirectevidenceofenterovirusinfectioninpancreatic
tissue of individuals with type 1 diabetes.
4546
Strengths and weaknesses
We made every effort to reduce potential bias in this
review, through use of pre-defined inclusion criteria,
Case-control studies
  Coutant 200232
  Moya-Suri 2005
33
  Sarmiento 2007
16
Subtotal (95% CI)
Test for heterogeneity: τ2=0.00, χ
2=0.79, df=2,
  P=0.67, I2=0%
Test for overall effect: z=3.41, P<0.001
Prospective studies
  Al-Shaheeb, 2010
30
  Graves, 2003
22 (siblings)
  Graves, 200322 (newborns)
  Sadeharju, 200328
  Salminen, 2003
20
  Salminen, 2004
29
Subtotal (95% CI)
Test for heterogeneity: τ2=0.27, χ2=7.86, df=5,
  P=0.16, I2=36%
Test for overall effect: z=3.11, P=0.002
Total (95% CI)
Total events: 122 (treatment), 118 (control)
Test for heterogeneity: τ2=0.20, χ
2=10.68, df=8,
  P=0.22, I2=25%
Test for overall effect: z=4.35, P<0.001
12.00 (0.63 to 230)
6.00 (1.24 to 29)
26 (1.38 to 482)
8.89 (2.53 to 31)
3.79 (1.16 to 12.43)
1.00 (0.16 to 6.20)
0.49 (0.09 to 2.81)
4.14 (1.43 to 11.94)
4.84 (1.65 to 14.22)
7.05 (1.40 to 35)
3.00 (1.50 to 6.00)
3.74 (2.06 to 6.78)
4
11
4
18
16
9
9
19
18
11
82
100
0.001 0.1 1 10 1000
Favours
control
Favours
case
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
1/5
10/50
5/32
16/87
5/13
3/13
2/13
9/19
7/41
10/12
52/198
52/198
Cases
1/49
2/50
0/64
3/163
28/198
3/13
7/26
15/84
8/196
22/53
86/733
86/733
Controls
Events/total
Fig 1 | Odds ratios for enterovirus positivity in patients with pre-diabetes versus no diabetes
Table 4 |Combined odds ratios for pre-diabetes studies stratified by study type
Type of study No of studies Combined OR (95% CI) P value χ2/df*
All 9 3.7 (2.1 to 6.8) <0.001 1.34
Nested case-control studies 6 3.0 (1.5 to 6.0) 0.002 1.57
Studies in Europe 5 5.2 (2.8 to 9.6) <0.001 0.17
*Cochrane χ
2 divided by degrees of freedom. Values >1 indicate heterogeneity.
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restriction,andsearchingofreferenceslistsandconfer-
enceproceedings.Weincludedstudiesinchildrenand
adults, reducing the risk of bias resulting from high
rates background infection in children.
4748 Studies
from throughout the world were included, reducing
the risk of geographical bias related to infection rates.
Moststudies,however,werefromEuropeancountries,
wheretheincidenceoftype1diabetesishigher.Given
the heterogeneity of the study populations, we used
random effects models, providing more conservative
effect estimates.
Several limitations could have influenced our find-
ings, including factors inherent in a meta-analysis of
observational studies. There was significant heteroge-
neity in study design and methods used. Only 10 stu-
dies matched for three or more potential confounding
factors (age, genetic risk, geographical location, and
sampling time). Most of the included studies used chil-
dren without diabetes or who were negative for anti-
bodies as controls, but there could have been
unmeasured factors influencing their risk of develop-
ing diabetes. Other environmental factors might mod-
ify the risk of type 1 diabetes, such as cows’ milk,
49
vitamin D,
50 and weight gain in infancy,
51 but it is not
possible to control for all of these potential confoun-
ders in case-control studies. Finally, enterovirus PCR
primershadvaryingsensitivityandspecificity,andnot
all studies reported the validation and limits of detec-
tionoftheirPCRmethod.Sampleswereobtainedfrom
various sites (serum, stool, throat swabs, etc) and
because enteroviruses invade and replicate at mucosal
surfaces, detection rates are likely to be higher in sam-
ples obtained from the gastrointestinal tract.
5253
The overall methodological quality of the studies of
the studies was relatively good, with 26 publications
scoring 5 or more of 9 on the Newcastle-Ottawa
scale. Eleven studies included fewer than 50 partici-
pants, giving rise to the possibility of small study
effects. The four largest studies of diabetes (involving
more than 1000 cases and controls), however, showed
a clear association between enterovirus infection and
clinical diabetes.
Strengths and weaknesses in relation to other studies
A previous meta-analysis of coxsackie B virus serolo-
gical studies found no significant association between
type 1 diabetes and serology positivity,
26 though sum-
mary estimates were not calculated because of signifi-
cant heterogeneity between studies. Several major
differences between the two meta-analyses could
explain the discrepant findings. Firstly, most studies
included in our review detected most enteroviruses
by using PCR primers targeting the highly conserved
5´ untranslated region of the enterovirus genome,
whereas serological studiesexamined only certain ser-
otypes. Secondly, molecular methods for detection of
enteroviruses are significantly more sensitive than
serology.
5455 Thirdly, the detection of enterovirus
RNAorvp1identifiesonlycurrentorrecentinfection.
The latter is also a limitation of molecular methods,
though this would probably cause bias towards
under-reporting of infection rates and estimation of a
lower than actual effect size. We could not examine
whether participants had multiple enterovirus infec-
tions or the same persistent infection before the devel-
opment of autoimmunity or type 1 diabetes.
Autoimmunity was mostly defined as a positive
result for at least one autoantibody associated with
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Fig 2 | Odds ratios for enterovirus positivity in patients with and without diabetes
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page 6 of 9 BMJ | ONLINE FIRST | bmj.comtype 1 diabetes, and the presence of a single antibody
does not confer a high lifetime risk of clinical diabetes
compared with positive results for multiple anti
bodies.
5657 Prospective studies are also limited by the
frequency of sample collection, which might be only
six or 12 months apart, and it is noteworthy that the
only prospective study reporting an odds ratio under
1 had the longest sampling intervals.
22 A temporal
association between seroconversion to autoimmunity
and infection could be under-reported because of lack
of sampling at the time of infection or seroconversion,
or both, in some individuals.
Maternal enterovirus infection might also be a risk
factor for autoimmunity and type 1 diabetes. We did
not specify maternal infection in our inclusion criteria,
though among the “eventual diabetes” group entero-
virus RNA was more commonly detected in dried
blood spots from newborn infants who subsequently
developedtype1diabetes.Twooftheincludedstudies
in the pre-diabetes group examined maternal entero-
virus infection by using serology and showed little or
no association between infection and subsequent
development of autoimmunity in their offspring.
2028
There is conflicting evidence as to whether the pre-
senceor absenceof highrisk HLA genotypesmodifies
the associationbetweenenterovirus infection and type
1 diabetes. Several groups have reported higher rates
of enterovirus infection in children with low risk HLA
genotypes.
1658 Unfortunately, we could not do a sub-
group analysis by HLA genotype in the diabetes
studiesbecausemost studiesdidnot doHLA genotyp-
ing in control participants. In the pre-diabetes group,
theoddsratioofenterovirusinfectioninhighriskHLA
participants (3.5) was not different from the overall
odds ratio (3.4), and the conflicting results from the
two studies with low risk participants do not support
anassociationbetweenenterovirusinfectionand auto-
immunity. Ideally, future studies should include indi-
viduals with low risk HLA genotypes to explore
whether genetic risk modifies the effect of enterovirus
infection on the risk of type 1 diabetes.
Conclusion
Our results show an association between type 1 dia-
betes and enterovirus infection, with a more than
nine times the risk of infection in cases of diabetes
andthreetimestheriskinchildrenwithautoimmunity.
The odds of having an enterovirus infection in people
with established diabetes (odds ratio 11) suggest that
persistent enterovirus infection is also common
among patients with type 1 diabetes. While it is not
possible to determine a causal relation between infec-
tion and type 1 diabetes with a randomised controlled
trial, larger multicentre international prospective stu-
dies could examine interactions between type 1 dia-
betes and various environmental, geographical, and
genetic factors.
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